These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 28537985)

  • 1. Neuroimaging in Parkinson's disease: focus on substantia nigra and nigro-striatal projection.
    Frosini D; Cosottini M; Volterrani D; Ceravolo R
    Curr Opin Neurol; 2017 Aug; 30(4):416-426. PubMed ID: 28537985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
    Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
    Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The spatiotemporal changes in dopamine, neuromelanin and iron characterizing Parkinson's disease.
    Biondetti E; Santin MD; Valabrègue R; Mangone G; Gaurav R; Pyatigorskaya N; Hutchison M; Yahia-Cherif L; Villain N; Habert MO; Arnulf I; Leu-Semenescu S; Dodet P; Vila M; Corvol JC; Vidailhet M; Lehéricy S
    Brain; 2021 Nov; 144(10):3114-3125. PubMed ID: 33978742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nigrostriatal dopamine transporter availability in early Parkinson's disease.
    Fazio P; Svenningsson P; Cselényi Z; Halldin C; Farde L; Varrone A
    Mov Disord; 2018 Apr; 33(4):592-599. PubMed ID: 29436751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Study of MRI Biomarkers in the Substantia Nigra to Discriminate Idiopathic Parkinson Disease.
    Pyatigorskaya N; Magnin B; Mongin M; Yahia-Cherif L; Valabregue R; Arnaldi D; Ewenczyk C; Poupon C; Vidailhet M; Lehéricy S
    AJNR Am J Neuroradiol; 2018 Aug; 39(8):1460-1467. PubMed ID: 29954816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spatiotemporal changes in substantia nigra neuromelanin content in Parkinson's disease.
    Biondetti E; Gaurav R; Yahia-Cherif L; Mangone G; Pyatigorskaya N; Valabrègue R; Ewenczyk C; Hutchison M; François C; Arnulf I; Corvol JC; Vidailhet M; Lehéricy S
    Brain; 2020 Sep; 143(9):2757-2770. PubMed ID: 32856056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative susceptibility mapping in atypical Parkinsonisms.
    Mazzucchi S; Frosini D; Costagli M; Del Prete E; Donatelli G; Cecchi P; Migaleddu G; Bonuccelli U; Ceravolo R; Cosottini M
    Neuroimage Clin; 2019; 24():101999. PubMed ID: 31539801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Axonal degeneration in Parkinson's disease - Basal ganglia circuitry and D2 receptor availability.
    Pelzer EA; Melzer C; Schönberger A; Hess M; Timmermann L; Eggers C; Tittgemeyer M
    Neuroimage Clin; 2019; 23():101906. PubMed ID: 31254937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging Neuroimaging Biomarkers Across Disease Stage in Parkinson Disease: A Review.
    Mitchell T; Lehéricy S; Chiu SY; Strafella AP; Stoessl AJ; Vaillancourt DE
    JAMA Neurol; 2021 Oct; 78(10):1262-1272. PubMed ID: 34459865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Substantia nigra echogenicity and imaging of striatal dopamine transporters in Parkinson's disease: a cross-sectional study.
    Bor-Seng-Shu E; Pedroso JL; Felicio AC; de Andrade DC; Teixeira MJ; Braga-Neto P; Batista IR; Barsottini OG; Borges V; Ferraz HB; Shih MC; Bressan RA; de Andrade LA; Walter U
    Parkinsonism Relat Disord; 2014 May; 20(5):477-81. PubMed ID: 24629800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive markers for Parkinson's disease using deep neural nets on neuromelanin sensitive MRI.
    Shinde S; Prasad S; Saboo Y; Kaushick R; Saini J; Pal PK; Ingalhalikar M
    Neuroimage Clin; 2019; 22():101748. PubMed ID: 30870733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multimodal MRI assessment of nigro-striatal pathway in multiple system atrophy and Parkinson disease.
    Barbagallo G; Sierra-Peña M; Nemmi F; Traon AP; Meissner WG; Rascol O; Péran P
    Mov Disord; 2016 Mar; 31(3):325-34. PubMed ID: 26676922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Striatal silent lacunar infarction is associated with changes to the substantia nigra in patients with early-stage Parkinson's disease: A diffusion kurtosis imaging study.
    Zhang G; Zhang Y; Zhang C; Wang Y; Ma G; Nie K; Xie H; Liu J; Wang L
    J Clin Neurosci; 2016 Nov; 33():138-141. PubMed ID: 27499120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Substantia nigra echogenicity: A structural correlate of functional impairment of the dopaminergic striatal projection in Parkinson's disease.
    Weise D; Lorenz R; Schliesser M; Schirbel A; Reiners K; Classen J
    Mov Disord; 2009 Aug; 24(11):1669-75. PubMed ID: 19514075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PET studies of the striatal dopaminergic system in Parkinson's disease (PD).
    Piccini P; Turjanski N; Brooks DJ
    J Neural Transm Suppl; 1995; 45():123-31. PubMed ID: 8748617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study [corrected].
    Iranzo A; Lomeña F; Stockner H; Valldeoriola F; Vilaseca I; Salamero M; Molinuevo JL; Serradell M; Duch J; Pavía J; Gallego J; Seppi K; Högl B; Tolosa E; Poewe W; Santamaria J;
    Lancet Neurol; 2010 Nov; 9(11):1070-7. PubMed ID: 20846908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Motor asymmetry and neuromelanin imaging: Concordance in Parkinson's disease.
    Prasad S; Saini J; Yadav R; Pal PK
    Parkinsonism Relat Disord; 2018 Aug; 53():28-32. PubMed ID: 29709506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Substantia Nigra Neuromelanin as an Imaging Biomarker of Disease Progression in Parkinson's Disease.
    Fabbri M; Reimão S; Carvalho M; Nunes RG; Abreu D; Guedes LC; Bouça R; Lobo PP; Godinho C; Coelho M; Gonçalves NC; Rosa MM; Antonini A; Ferreira JJ
    J Parkinsons Dis; 2017; 7(3):491-501. PubMed ID: 28671143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three-dimensional neuromelanin-sensitive magnetic resonance imaging of the substantia nigra in Parkinson's disease.
    Prasad S; Stezin A; Lenka A; George L; Saini J; Yadav R; Pal PK
    Eur J Neurol; 2018 Apr; 25(4):680-686. PubMed ID: 29341412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative [(123)I]FP-CIT pinhole SPECT imaging predicts striatal dopamine levels, but not number of nigral neurons in different mouse models of Parkinson's disease.
    Alvarez-Fischer D; Blessmann G; Trosowski C; Béhé M; Schurrat T; Hartmann A; Behr TM; Oertel WH; Höglinger GU; Höffken H
    Neuroimage; 2007 Oct; 38(1):5-12. PubMed ID: 17716921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.